Phibro Animal Health/$PAHC
1D1W1MYTD1Y5YMAX
Capital at risk
About Phibro Animal Health
Phibro Animal Health Corp is a world-wide diversified animal health and mineral nutrition company. It strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. It develop, manufacture and market products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. It has three segments Animal Health, Mineral Nutrition, and Performance Products. Majority of revenue comes from Animal Health segment. Animal health products are anti-bacterials, anticoccidials, nutritional specialty products, and vaccines, and vaccine adjuvants that help improve the animal's health.
- Ticker
- $PAHC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,605
- Headquarters
- Teaneck, United States
- Website
- www.pahc.com
PAHC Metrics
BasicAdvanced
$1.5B
14.76
$2.43
0.46
$0.48
1.34%
Price and volume
Market cap
$1.5B
Beta
0.46
52-week high
$60.08
52-week low
$28.25
Average daily volume
260K
Dividend rate
$0.48
Financial strength
Current ratio
2.956
Quick ratio
1.02
Long term debt to equity
1.954
Total debt to equity
2.064
Dividend payout ratio (TTM)
19.52%
Interest coverage (TTM)
4.18%
Profitability
EBITDA (TTM)
244.231
Gross margin (TTM)
33.33%
Net profit margin (TTM)
6.57%
Operating margin (TTM)
12.80%
Effective tax rate (TTM)
27.39%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
8.48%
Return on equity (TTM)
29.72%
Valuation
Price to earnings (TTM)
14.761
Price to revenue (TTM)
0.958
Price to book
3.77
Price to tangible book (TTM)
4.93
Price to free cash flow (TTM)
147.414
Free cash flow yield (TTM)
0.68%
Free cash flow per share (TTM)
0.243
Dividend yield (TTM)
1.34%
Forward dividend yield
1.34%
Growth
Revenue change (TTM)
17.12%
Earnings per share change (TTM)
104.20%
3-year revenue growth (CAGR)
15.79%
10-year revenue growth (CAGR)
7.28%
3-year earnings per share growth (CAGR)
44.52%
10-year earnings per share growth (CAGR)
1.62%
10-year dividend per share growth (CAGR)
1.84%
What the Analysts think about PAHC
Analyst ratings (Buy, Hold, Sell) for Phibro Animal Health stock.
Analyst projections of the future price of Phibro Animal Health stock.
Bulls say / Bears say
Phibro delivered strong fiscal 2026 results: sales rose 17%, adjusted EBITDA 39% and adjusted diluted EPS 48%. Animal Health sales increased 21%, showing that the Zoetis medicated feed additive acquisition is translating into higher earnings. (Business Wire)
The completed Phibro Forward programme is expected to contribute about $50 million of cumulative EBITDA by fiscal 2027 versus its fiscal 2024 baseline. Closing the Chicago Heights plant should add a further estimated $15 million to $20 million of annual EBITDA savings from fiscal 2028, if the production transfer runs smoothly. (StockAnalysis, Investing.com)
Growth is broadening beyond the acquired portfolio: fiscal 2026 vaccine sales rose 14%, nutritional specialties 9% and Mineral Nutrition 11%. New vaccine capacity and the Verratain sustainability platform give Phibro additional avenues for growth in animal health, feed and companion-animal markets. (Animal Health News, Business Wire)
Brazil’s new antimicrobial rules prohibit performance-enhancing uses of products including virginiamycin, while required therapeutic registrations remain pending. Phibro generated about $27 million from Brazilian virginiamycin in fiscal 2026, and its fiscal 2027 guidance assumes minimal sales; other antimicrobial products also face regulatory scrutiny. (Business Wire, StockTitan)
Cash conversion is weak relative to reported profit: fiscal 2026 free cash flow was only $9.9 million against $255 million of adjusted EBITDA. Total debt was $737.9 million, while interest expense rose 28% to $44.4 million, leaving less flexibility if growth disappoints. (StockTitan, Last10K)
The easy acquisition comparison is fading: the acquired MFA portfolio fell 11% in the fourth quarter, and fiscal 2027 guidance slows to roughly 4% sales growth and 3% adjusted EBITDA growth after fiscal 2026’s 17% and 39% increases. Higher SG&A and the Chicago Heights production transfer could further pressure near-term operating momentum. (StockAnalysis, Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Sept 2026.
PAHC Financial Performance
Revenues and expenses
PAHC Earnings Performance
Company profitability
Upcoming events
No upcoming events
PAHC News
AllArticlesVideos
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference
Business Wire3 weeks ago
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Business Wire1 month ago
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
Business Wire1 month ago
Funds containing PAHC
AllUSDGBPEUR
Fund name | Fund size | $PAHC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.